Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

PFS Clinical Trial

Official title:
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients

Status Recruiting

Clinical Trial Summary

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04425187
Study type	Interventional
Source	Fudan University
Contact	wang jia lei, doctor
Phone	18017312369
Email	haitunqiao@hotmail.com
Status	Recruiting
Phase	Phase 2
Start date	June 8, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05638984` - Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05267366` - Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC	Phase 2
Recruiting	`NCT05267288` - Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02629718` - Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer	Phase 3
Recruiting	`NCT04520035` - Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell	Phase 2